VAS
CRSP icon

Vestmark Advisory Solutions’s CRISPR Therapeutics CRSP Stock Holding History

Vestmark Advisory Solutions’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2M Buy
256,779
+7,231
+3% +$381K 0.14% 163
2025
Q4 		$13.1M Buy
249,548
+10,586
+4% +$634K 0.18% 114
2025
Q3 		$15.5M Sell
238,962
-246,013
-51% -$14.1M 0.3% 68
2025
Q2 		$23.6M Buy
484,975
+259,669
+115% +$10M 0.34% 66
2025
Q1 		$7.67M Sell
225,306
-18,728
-8% -$794K 0.2% 137
2024
Q4 		$10.8M Buy
244,034
+69,937
+40% +$3.3M 0.37% 57
2024
Q3 		$8.18M Sell
174,097
-23,517
-12% -$1.19M 0.3% 66
2024
Q2 		$10.7M Sell
197,614
-51,930
-21% -$3M 0.45% 45
2024
Q1 		$17M Buy
249,544
+76,256
+44% +$5.46M 0.73% 30
2023
Q4 		$10.8M Buy
+173,288
New +$9.58M 0.55% 35

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return